機能性ペプチド融合によるInterferon γ時空間制御

DOI HANDLE Web Site Web Site PubMed 参考文献39件 オープンアクセス
  • 安藤 満
    京都大学大学院薬学研究科病態情報薬学分野
  • 高橋 有己
    京都大学大学院薬学研究科病態情報薬学分野
  • 西川 元也
    京都大学大学院薬学研究科病態情報薬学分野
  • 高倉 喜信
    京都大学大学院薬学研究科病態情報薬学分野

書誌事項

タイトル別名
  • Control of Spatiotemporal Distribution of Interferon γ by Genetically Fusing Functional Peptides
  • キノウセイ ペプチド ユウゴウ ニ ヨル Interferon gジクウカン セイギョ

この論文をさがす

抄録

  Type II interferon (IFNγ) is a representative Th1 cytokine and it possesses a variety of functions, including immune regulation, antiviral and antitumor activity. Because of its multifunctional nature, IFNγ is expected to be applied to the treatment of autoimmune diseases, cancer and viral infection. Although IFNγ has therapeutic potential for such diseases, the clinical use of IFNγ has been limited due to its short in vivo half-life and serious adverse effects. In contrast, gene delivery of IFNγ is an alternative approach to increasing the retention time of IFNγ. To extend transgene expression after plasmid DNA (pDNA) gene transfer, we designed and developed pDNA with varying numbers of CpG motifs. CpG-reduced pDNA resulted in more durable transgene expression than its CpG replete counterpart in mice. Comparison of the effect of promoter/enhancer elements on transgene expression showed that ROSA26 promoter-mediated IFNγ expression was safe because of the lack of an initial surge after hydrodynamic gene transfer. We also designed an IFNγ-mouse serum albumin (MSA) fusion protein, IFNγ-MSA. Gene transfer of this fusion protein resulted in a sustained concentration of IFNγ fusion protein in mouse serum, and inhibited tumor metastasis in mice. These results provide experimental evidence that IFNγ gene therapy can be a useful treatment for a variety of diseases.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 132 (12), 1399-1406, 2012-12-01

    公益社団法人 日本薬学会

参考文献 (39)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ